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Abstract
Background: Whole lung lavage (WLL) is the current standard of care treatment for patients affected by pulmonary
alveolar proteinosis (PAP). However, WLL is not standardized and international consensus documents are lacking.
Our aim was to obtain a factual portrayal of WLL as currently practiced with respect to the procedure, indications
for its use, evaluation of therapeutic benefit and complication rate.
Methods: A clinical practice survey was conducted globally by means of a questionnaire and included 27 centers
performing WLL in pediatric and/or adult PAP patients.
Results: We collected completed questionnaires from 20 centres in 14 countries, practicing WLL in adults and 10
centers in 6 countries, practicing WLL in pediatric patients.
WLL is almost universally performed under general anesthesia, with a double-lumen endobronchial tube in two
consecutive sessions, with an interval of 1–2 weeks between sessions in approximately 50 % of centres. The use of
saline warmed to 37 °C, drainage of lung lavage fluid by gravity and indications for WLL therapy in PAP were
homogenous across centres.
There was great variation in the choice of the first lung to be lavaged: 50 % of centres based the choice on
imaging, whereas 50 % always started with the left lung. The choice of position was also widely discordant; the
supine position was chosen by 50 % of centres. Other aspects varied significantly among centres including
contraindications, methods and timing of follow up, use of chest percussion, timing of extubation following WLL
and lung isolation and lavage methods for small children. The amount of fluid used to perform the WLL is a critical
aspect. Whilst a general consensus exists on the single aliquot of fluid for lavage (around 800 ml of warm saline, in
adults) great variability exists in the total volume instilled per lung, ranging from 5 to 40 liters, with an average of
15.4 liters/lung.
Conclusions: This international survey found that WLL is safe and effective as therapy for PAP. However these
results also indicate that standardization of the procedure is required; the present survey represents the a first step
toward building such a document.
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Background
Whole lung lavage (WLL) is a therapeutic procedure [1]
used to treat pulmonary alveolar proteinosis (PAP), a
rare syndrome occurring in a heterogeneous group of
lung diseases characterized by accumulation of lipopro-
teinaceous material in the alveoli, whicht impairs oxygen
uptake and causes hypoxemic respiratory failure [2, 3].
Therapeutic efficacy derives from removal of the accu-
mulated lipoproteinaceous material – primarily surfac-
tant and necrotic cell debris – by physically ‘washing’
the alveoli with saline. WLL is usually performed under
general anesthesia with lung separation obtained by a
double-lumen endobronchial tube. While mechanical
ventilation is maintained in one lung, the contralateral
lung is repeatedly filled with saline and then drained by
gravity. Typically, the lavage is accompanied by chest
percussion to emulsify the surfactant sediment, and is
continued until the lavage fluid becomes clear, usually
judged by visual inspection.
Presently applied WLL procedures are based on the
first description by Juan Ramirez Rivera in 1963 [1], but
several centres have introduced modifications with the
aim of improving the original method [4]. Although
widely considered as the standard-of-care for auto-
immune PAP [5], the WLL procedure, indications for its
use, and the criteria to measure outcome have not been
standardized among centres. Nor has the therapeutic
effectiveness been compared for different secondary PAP
syndromes. Further, centre-specific indications have never
been compared, integrated to optimize or standardize
WLL, or systematically disseminated. Moreover training
on how to perform WLL involves an apprenticeship or in
many cases is self taught; which obviously leads to add-
itional variations among centres.
To begin laying the foundation for a consensus and
experience-based, best-practice standardization of WLL,
physicians performing WLL were surveyed by question-
naire on a global scale. Results concern the practice of
WLL in adult and paediatric patients and include
information on the procedure itself, local modifications,
indications for use, contraindications, procedural moni-
toring, criteria to measure outcomes and complication
rates.
Methods
WLL questionnaire development
This study was conducted as part of the e-RARE 2009
EuPAPnet study (http://www.alveolarproteinosis.eu/). An
international ad hoc committee of physicians performing
WLL and/or caring for PAP patients developed the sur-
vey questionnaire, which includes sections for physicians
only performing WLL in either adult (≥18 years-old) or
paediatric (<18 years-old) patients; only lobar or seg-
mental bronchoscopic lavage (LSBL) in adult and/or
paediatric patients; or both WLL and LSBL. The ques-
tionnaire is available in the Additional file 1.
Data collection
The study cohort included physicians performing
therapeutic lung lavage. Potential partecipants were
identified either through a PubMed search (http://
www.ncbi.nlm.nih.gov/pubmed) using the search terms
‘pulmonary proteinosis’, ‘alveolar proteinosis’, ‘alveolar
phospholipidosis’, ‘lung lavage’, and ‘whole lung lavage’; or
invited by an announcement placed in the European
Respiratory Journal [6] or directly contacted: i.e., members
of the international paediatric interstitial lung disease net-
work; and acquaintances of steering committee members.
Potential respondents were contacted by e-mail, interested
individuals received the questionnaire by email, and all
completed questionnaires that were returned were in-
cluded in the analysis. All respondents gave written
authorization for their responses to be included in the
study.
Analysis
Numeric variables were evaluated for normality with the
Shapiro-Wilk test and expressed as the mean +/− SD or
median +/− the interquartile range (IQR) as appropriate.
Comparisons were made by one-way ANOVA with the
Bonferroni correction. Categorical data were summa-
rized numerically or expressed as a percentage and com-
pared using the chi square or Fisher’s exact test as
appropriate. Correlations among continuous variables
were made using Pearson’s correlation coefficient. All
comparisons were two-sided. P values of <0.05 were
considered statistically significant. Analyses were per-
formed using STATA, version 13.1 (Stata Corporation,
College Station, Texas, USA). Three categories for the
number of times WLL was conducted in a single patient
(WLL < 2, ≥2 WLL <3, WLL >3) were utilized in analyz-
ing results related to clinical outcomes.
Data were considered in a two-stage IPD meta-
analysis, in order to correct the unavailability of single
patient data. In the first stage, each individual study was
analyzed as described in the meta-analysis protocol or
analysis plan. As a second step, the results, or summary
statistics, of each of these individual study analyses were
combined to provide a pooled estimate of effect, as for a
conventional systematic review.
Results
Of the 79 centres identified worldwide that provide
therapeutic lung lavage (52 centres in adults, 27 in
children), 40 (50 %) expressed an interest in the study
and were sent the questionnaire; of these 27 (33 %) com-
pleted and returned the documents (Table 1). Among
these, seventeen centres treat only adults (14 only WLL,
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no one only SLBL, 3 both WLL and SLBL), seven treat
only children (1 only WLL, 3 only SLBL, 3 both WLL
and SLBL), and three treat both (2 only WLL, no one
only SLBL, 1 both WLL and SLBL). Among centres pro-
viding both WLL and SLBL, WLL is considered the
standard-of-care and SLBL treatment is reserved for
patients judged unable to tolerate WLL. SLBL was also
used in young children for whom double lumen
endobronchial tubes of sufficiently small diameter are
unavailable, and also to predict the therapeutic effect-
iveness of WLL in patients in whom this was uncer-
tain, e.g., those with Niemann Pick disease.
1. WLL in Adult Patients
Twenty centres reported performing WLL in adults
(Table 1). The mean (+/− SD) duration of experience
was 18 +/− 11 years and varied substantially among
centres (Fig. 1a). The mean number of WLL procedures
performed annually per centre was 5.61 +/− 5.04 and
also varied among centres (Fig. 1b).
Indications and contraindications for WLL therapy
Indications for WLL varied among centres (Table 2).
Specific indications included an unspecified decline in
lung function, a decline in resting PaO2, worsening of
lung disease severity judged radiographically based on a
comparison of serial chest computed tomograms or
chest radiograms (using visual assessment in all except
two centres that use semi-quantitative criteria), decline
in diffusing carbon monoxide capacity (DLCO), decline
in forced vital capacity (FVC), decline in resting oxygen
saturation by pulse oximetry (SpO2) or an increase in
respiratory symptoms.
Three centres also reported using WLL for indications
other than PAP, including: accidental inhalation of
Table 1 Centres participating in the survey
Centre WLL SLBL Adult Paediatric
Sheffield Children’s Hospital, UK X X X
Royal Brompton Hospital, London, UK X X X X
Sheba Medical Centre, Tel-Hashomer, Tel Aviv U., Israel X X X
Children’s Hospital Boston, USA X X
Kinderklinik und Kinderpoliklinik im, U. of Munich, Germany X X X
Cincinnati Children’s Hospital, USA X X X
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy X X
University of North Carolina at Chapel Hill, USA X X
Hacettepe University, Ankara, Turkey X X
U. Witwatersrand, Johannesburg, South Africa X X
Pavlov State Medical University, St. Petersburg, Russian Federation X X X
NHO Kinki-Chuo Chest Medical Centre, Osaka, Japan X X X
U. Medical College, Hangzhou, Zhejiang, China X X X
Lungenclinic Grosshandorf, Germany X X
U. Hospital, Olomouc, Czech Republic X X
Asklepios-Fachkliniken München Gauting, Germany X X
Helsinki University Central Hospital, Finland X X
Dept. of Respiratory Medicine, Cork University Hospital, Ireland X X
Care Medicine Thoraxklinik, Heidelberg, Germany X X
Serviço de Pneumologia- Hospital São João-Porto, Portugal X X
Ruhrlandklinik-University of Duisburg Essen, Germany X X
Pulmonary Division, University Hospital, Zurich, Switzerland X X
Hopital Louis Pradel, Lyon, France X X
Tokyo Medical U. Hachioji Medical Centre, Japan X X
Kantonsspidal Aarau, Switzerland X X
St. Antonius Hospital Nieuwegein, The Netherlands X X
Kempten-Oberallgäu Hospital, Immenstadt, Germany X X X
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activated charcoal, alveolar hemorrhage, silicoproteino-
sis, lipoid pneumonia, silicosis or cryptogenic fibrosing
alveolitis (CFA).
Contraindications to WLL were applied by six centres
and included severe cardiovascular disease, heart failure,
sepsis, significant lung infection and end-stage pulmon-
ary fibrosis.
Interval between treatment of right and left lungs
Most (17/20) centres performed WLL in separate ses-
sions on each lung for a given patient. The time separat-
ing WLL therapy for each lung was 2.9 ± 1.18 weeks and
a)
b)
Fig. 1 a. Years’ experience of each centre in performing WLL in adult PAP patients. b. Mean number of WLLs performed per centre annually, in
adult PAP patients
Table 2 Indications for WLL therapy
Indications for WLL % of centres
Unspecified decline in lung function 100
Decline in resting PaO2 90
Chest X-ray or CT 79
Decline in DLCO 70
Decline in FVC 63
Decline in SpO2 58
Symptoms 42
Other 15
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varied from 24 h at one centre to 6–12 weeks at another
centre. Only one centre routinely treated both lungs in
one session, while two other centres treated lungs in
one or two sequential sessions depending on patient
tolerance.
Number of WLL treatments Per patient required in
autoimmune PAP
Of the approximate 368 PAP patients for whom data was
evaluated, the number of WLL procedures received by
PAP patients during the follow-up period was 2.5 +/− 1.5
in five years. Of these patients, two thirds required one
lavage, and only 10 % required more than five WLL proce-
dures (Fig. 2). The interval between consecutive bilateral
WLL procedures was 8 +/− 6.45 months but varied from
1 week to several years.
Because the clinical course of autoimmune PAP is
variable, we evaluated whether the experience of the
centre (number of years in activity and number of WLL
procedures performed annually) and the volumes used
for WLL might relate to clinical outcome. We found no
correlation in these parameters (χ2 = 0.1238 and 0.4905,
respectively) suggesting that neither the experience level
or volume of WLL fluid used were significantly corre-
lated with clinical outcome.
Complications in WLL
Based on an estimated 1110 WLL procedures, the cen-
tres reported specific complication rates ranging from a
median of 16 % for transient fever (the most common
complication) to 0.8 % for pneumothorax (Table 3).
Follow up after lung lavage therapy
All centres reported performing a short-term assessment
(chest x-ray and functional assessment) after WLL over
a period that ranged from 2 h to 2 weeks. Some (9/20)
centres also performed a follow up chest computed
tomogram (CT) scan at a variable time ranging from
7 days to 6 months. All centres reported performing
medium- to long-term follow up using conventional
radiological and functional parameters including chest
CT scan (12/20 centres – routinely at 8, and on an
‘as indicated basis’ at 4 months). Six centres per-
formed follow up biomarker evaluations including
serum LDH, GM-CSF autoantibody levels and less
commonly SPA, SPD, KL-6, CEA, Cyfra 21–1. Two
Fig. 2 Stratification of adult autoimmune PAP patients according to the number of WLL procedures received
Table 3 Complications in WLL
Complication Frequency (%)a, b
Fever 18.0
Fluid leakage 4.0
Hypoxemia 14.2
Wheezing 6.1
Pneumonia 5.0
Headache 0
Respiratory acidosis 0
Transient neuropathy 0
Pleural effusion 3.1
Prolonged mechanical ventilation 0
Metabolic acidosis 0
Pulmonary thromboembolism 0
Pneumothorax 0.8
Transient cardiac ischemia 0
Cardiac arrest 1.1c
aBased on an estimated total of 1110 WLLs. Estimation of the total number of
WLLs is the sum of the total per centre calculated as: median WLL number per
year multiplied by the number of years’ experience
bThe frequency of complications was estimated as the mean value of frequencies
reported by the centres
cCardiac arrest occurred only in 1 case out of 5 WLL reported, only at 1 centre
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centres followed up WLL procedures by using a qual-
ity of life questionnaire.
Implementation of the WLL procedure
Lung isolation
The lungs must be isolated during WLL so that one can
be lavaged while the other is ventilated to maintain the
necessary gas exchange. This is usually achieved by posi-
tioning a double-lumen endobronchial tube, which en-
sure an adequate seal to prevent fluid spillage from the
treated lung into the ventilated lung. A left-sided
double-lumen endobronchial tube is the most common
choice in adults and larger children. The minimum size
of the double-lumen tube is 26 Fr.
Anesthesia
At all centres, WLL is performed under general
anesthesia (Additional file 2: Table S1), typically by intra-
venous anesthesia, most commonly with a combination
of propofol, an opioid and a neuro-muscular blocking
agent. Two centres use volatile anesthetic agents. At
about half the centres (9/20), a procedure referred to as
‘lung atelectasis/degassing’ is performed prior to WLL.
Patient parameters typically monitored during WLL are
indicated in Table 4.
Lung selection
The method used to decide which lung to treat first var-
ied among centres. About half (12/20) used radiographic
information to identify and treat the more severely af-
fected lung first, which was based on visual inspection of
the chest CT (9 centres), chest x-ray (2 centres), or a
combination of chest x-ray and CT (1 centre). At six
centres, the decision was independent of lung-specific
severity: the left lung was always treated first, due to its
smaller relative size. At about half of the centres (9/20),
a procedure referred to as ‘lung atelectasis/degassing’ is
performed prior to starting the lavage of each lung. De-
gassing of one lung is obtained by ventilation with 100 %
oxygen followed by forced lung deflation with negative
airway pressure and subsequent airway opening occlu-
sion maintained for 10 to 15 min up to absorption atel-
ectasis of the whole lung. Lung degassing is intended to
help the lavage fluid reach the alveoli more easily and
evenly.
Patient position
The position of the patient during WLL varied consider-
ably among centres: 12 (60 %) centres utilized a supine
position; 6 (30 %) centres utilized a full lateral position
at 90°; 2 centres utilized a moderate lateral position at
30° to 45° inclination. Of those utilizing a lateral pos-
ition, all but one centre ventilated the non-dependent
lung and lavaged the dependent lung. Only one centre
uses a combination of full lateral position, dependent
lung ventilation and non-dependent lung lavage, having
observed better oxygenation due to better ventilation/
perfusion matching, no problems with lavage spillover
and more convenient access of the lavaged lung for
manual chest percussion. Moreover, 7 centres indicated
that patient positioning included the Trendelenburg pos-
ition to improve lavage recovery and increase alveolar
clearance.
Lavage fluid and administration
All Centres used saline warmed to 37 °C for WLL.
Supplements used at some centres included (number of
centres using the supplement): N-acetyl cysteine (1), am-
inophylline (1), hydrocortisone (1), sodium bicarbonate
(2) and gaseous oxygen (1). One centre modified the
filling-drainage cycle by adding manual ventilation of the
lavaged lung half-way through the draining time,
intended to improve the removal of material from the
lung [7]. All centres infused saline by gravity. One centre
used a specified hydrostatic head of 30 cm relative to the
mid-thorax.
The volume of saline aliquots infused during repeated,
sequential lung lavage varied greatly, ranging from 80
(SLBL) to 1,650 ml (WLL), with an average of 800 ±
331 ml. The total lavage volume also varied widely
among centres, ranging from 5 to 40 litres with most
(13/20) centres using less than 18 litres per lung (Fig. 3).
The mean total volume among the 20 centres was
15.4 +/− 6.8 litres per lung. Only one centre regularly
utilized a fixed volume (12 litres per lung).
Chest percussion
Most (14/20) centres used chest percussion to emulsify
the PAP sediment (~90 % lipid) in order to improve
therapeutic efficiency. However, the method and timing
varied greatly. Ten (50 %) centres utilized manual chest
percussion and four (20 %) centres used mechanical per-
cussion. The timing of chest percussion also varied with
Table 4 Parameters monitored during anesthesia/WLL
Parameter monitored N° of centres (%)
EKG 20 (100 %)
SaO2 18 (90 %)
Non invasive blood pressure 13 (65 %)
End tital CO2 13 (65 %)
Arterial catheter blood pressure 11 (55 %)
CVC 7 (35 %)
Bispectral index 3 (15 %)
Blood gas analysis 3 (15 %)
Pulmonary compliance 1 (5 %)
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some centres utilizing it during the entirety of each
infusion-drainage cycle, some during the drainage por-
tion only, some only after filling.
Duration and termination
The duration of WLL for one lung varied from 2 to 6 h
with an average of 6 +/− 1 h for both lungs. All centres
terminated WLL when the drained fluid became mark-
edly less cloudy than observed at the start of therapy;
this was usually based on visual inspection of the gross
appearance of the recovered fluid. Two centres also used
an objective measure of protein content.
Recovery period
Mechanical ventilation of both lungs in the intensive
care unit (ICU) was maintained from 20 min to 19 h
after completion of WLL, with an average of 5 +/− 1.5 h.
Most patients were discharged from the ICU within 5 h
after extubation.
2. Lung Lavage in Paediatric Patients
Seven centres reported performing lung lavage in
paediatric patients (4 - WLL or SLBL, 3 only WLL).
Three additional centres perform lung lavage only by
bronchoscopy (Table 1). The mean (+/− SEM) duration
of experience was 16 +/− 17 years, but this varied
among centres (not shown). The mean number of
SLBL procedures performed annually per centre was
5.75 +/− 5.83 and also varied among centres (not
shown). The average number of WLL treatments per
paediatric PAP patient (2.3 ± 1.52) was similar to that of
adults (2.5 ± 1.48). Indicators for pediatric WLL were also
similar to those for adults. The interval between WLL
treatment for each lung was on 5 +/− 2.8 days. All centres
used warm saline without additives. The volume of saline
infused ranged from 250 to 500 ml per aliquot. One centre
infused saline under a hydrostatic pressure of 30–40 cm
H2O. The total volume applied per lung varied from 4 to
14 litres. Three centres applied chest percussion, two of
them manually and one mechanically either during the
filling or drainage periods. The average duration of WLL
in children was 3.5 h. Smaller patients were weaned from
mechanical ventilation over a period of between 2 and
48 h with a mean of 12.7 +/− 23.5 h. Follow up evaluation
after WLL was similar to that of adult PAP patients except
that CT scans were not routinely used. In contrast to
adults, paediatric PAP patients received a greater number
of lavage procedures (Fig. 4), possibly because of differing
disease (i.e., GM-CSFRa deficiency instead of autoimmune
PAP) or the more frequent use of SLBL, which treats only
a segment or lobe, rather than WLL, which treats the en-
tire lung. At one centre, the intubation method for chil-
dren, as well as the decision to perform WLL or lobar/
segmental lavage via bronchoscopy, is based on patient
size. In children large enough to possibly tolerate a double
lumen tube, single-lumen endotracheal tubes of increasing
diameter are first ‘test-fitted’ to identify the maximum
possible size while avoiding subglottic trauma. Intubation
is then performed with a double-lumen tube of the size
identified. For children too small for a double-lumen tube,
intubation of the lung to be lavaged is achieved with a
single-lumen endotracheal tube, while ventilation of the
other lung is achieved by ventilating the trachea around
the endotracheal tube. The most frequent complications
of WLL in children are reported in Table 5.
Discussion
As a first step in developing an evidence-based, best-
practice approach to standardizing WLL therapy in PAP,
we made the results of a global survey of physicians
performing WLL in adults and children. Respondents
Fig. 3 Stratification of total amount of fluid (litres) used to lavage a single lung
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included 20 centres in 14 countries performing WLL in
adults and 10 centres in 6 countries performing WLL in
paediatric patients. Some aspects of WLL were similar
among centres, including the method for selecting the
first lung to be treated, treatment of each lung at differ-
ent sessions separated by several days to weeks, use of
general anesthesia, a double-lumen endotracheal tube
(in adults), saline warmed to 37 °C, and drainage of lung
lavage fluid by gravity. Other aspects of the procedure
varied significantly among centres, including indications
for treatment, contraindications, methods and timing of
the follow up evaluation, patient position during WLL,
the volume of saline infused, use of chest percussion,
timing of extubation after WLL and lung isolation and
lavage methods for small children. The length of experi-
ence among centres varied widely, but the overall rate of
serious, procedure-related complications was low. Lim-
ited number of diseases requiring WLL therapy, proced-
ural variations and their relationship to differences in
outcomes among patients and centres, all support the
need for integrated data from multiple centres in order
to develop a best-practices approach to standardizing
WLL therapy.
Important findings of our WLL survey include: in spite
of its clear therapeutic usefulness, it is not available at
most medical centres; it is frequently taught by informal
apprenticeship or is even self-taught and it varies among
centres with respect to the procedure itself, indications
for use, and assessment of benefit. We found 161 reports
on the use of WLL therapy for PAP in the NCBI
PubMed database including several technical descrip-
tions [8–12]. There was a consensus on indications for
WLL therapy in PAP, which included worsening of lung
function/gas exchange (100 % of centres), followed by
radiographic evidence of deterioration (79 %), and then
symptomatic worsening (42 % of centres). Notwithstand-
ing this consensus, the parameter used to determine
each varied considerably among centres. Even though
the majority of centres used ca. 800 ml of warmed saline
for each single infusion during WLL, centres varied in
their use and choice of additives, and the total volume of
saline used to treat each lung. These differences have
important implications for the conduct of clinical trials
evaluating new therapeutic approaches.
Interestingly, only 65 % of the centres employed an
observation period before performing the WLL. With
the exception of rapidly progressive cases, this would be
advisable as spontaneous improvement is possible. Even
though, complete spontaneous remission, previously
believed to occur in up to 30 % of cases [13], is now
known not to exceed 10 % of cases [14, 15].
The absence of an association between variability in
the clinical course among PAP patients (indicated by the
different number of WLL treatments needed to obtain
remission) and differences WLL practice among centres
(volume of saline used, number of procedures performed
annually, length of experience performing WLL) suggest
that intrinsic disease characteristics predominate over
Fig. 4 Stratification of paediatric PAP patients according to the number of procedures received
Table 5 Complications of WLL in children
Complication Overall occurrence rate
Hypoxemia 13 %
Fluid leakage 6 %
Pleural effusion 6 %
Fever 5 %
Wheezing 3 %
Pneumonia 3 %
Pneumothorax 1 %
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technical differences and experience in applying WLL
among centres. On the other hand, the low number of
complications and absence of a correlation with experi-
ence status may be related to the fact that the centres
filling out the questionnaire were all relatively experi-
enced. In fact, several authors stated that they treated
patients who were sent for a tertiary referral after a com-
plicated WLL procedure in an inexperienced hospital.
Although WLL is an invasive procedure, it has been
determined to be safe and associated with a low rate of
procedure-related morbidity (~18 %, including, in order
of decreasing frequency, fever, spillage of saline into the
ventilated lung, and worsened hypoxemia). SLBL [16] is
an alternative to WLL and is regarded as less invasive,
but neither its therapeutic effectiveness, nor its rate of
complications have been adequately studied and thus
was not considered in the present study.
This study has some limitations, which interfere with
the statistical analysis of the results, notably: the incom-
plete participation of physicians/centres who are known
to practice WLL therapy. Thus, our results may not
adequately reflect the practice of WLL at all centres or,
potentially, important improvements made at centres
not surveyed. Notwithstanding these limitations, these
results provide the first useful data for developing con-
sensus documents regarding technical implementation,
indications, and evaluation of WLL therapy. For this
reason, the questionnaire has been included in an
Additional file 1 for use by other centres wishing to pro-
vide additional data regarding their centre’s practice of
WLL. Even though few centres performing WLL in chil-
dren were identified/included, one important problem
identified with this survey was the lack of availability of
double lumen endotracheal tubes of sufficiently small
size for use in small children.
Conclusions
Our study (as well as the literature) provides data for the
development of a consensus document and experience-
based, best-practice standardization of WLL. We con-
clude that the assembly of an international task force on
the conduct of WLL therapy in adults and children
would be helpful in this regard.
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Additional file 1: Therapeutic lavage for pulmonary alveolar proteinosis.
A questionnaire for an international survey. (DOCX 126 kb)
Additional file 2: Pharmacologic approaches utilized to support WLL.
(DOCX 14 kb)
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